◈ Viewsifter News
← Back to today's digest
‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
📰 MarketWatch Top Stories
·
NA
📊 macro
· 2026-10-13
The Federal Trade Commission and seven states say Shkreli should be held in contempt.
Read original article →